-
Je něco špatně v tomto záznamu ?
Involvement of deleted chromosome 5 in complex chromosomal aberrations in newly diagnosed myelodysplastic syndromes (MDS) is correlated with extremely adverse prognosis
Z. Zemanova, K. Michalova, H. Buryova, J. Brezinova, K. Kostylkova, D. Bystricka, M. Novakova, I. Sarova, S. Izakova, L. Lizcova, S. Ransdorfova, Z. Krejcik, MD. Merkerova, A. Dohnalova, M. Siskova, A. Jonasova, R. Neuwirtova, J. Cermak,
Leukemia research.
2014 ;
38 (5) :
537-44.
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, práce podpořená grantem
Perzistentní odkaz
https://www.medvik.cz/link/bmc14063686
- MeSH
- chromozomální delece * MeSH
- dospělí MeSH
- karyotyp MeSH
- lidé středního věku MeSH
- lidé MeSH
- lidské chromozomy, pár 5 * MeSH
- myelodysplastické syndromy genetika mortalita MeSH
- prognóza MeSH
- retrospektivní studie MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- srovnávací genomová hybridizace MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
MDS with complex chromosomal aberrations (CCA) are characterized by short survival and a high rate of transformation to AML. A comprehensive genome-wide analysis of bone-marrow cells of 157 adults with newly diagnosed MDS and CCA revealed a large spectrum of nonrandom genomic changes related to the advanced stages of MDS. Chromosome shattering, probably resulting from chromothripsis, was found in 47% of patients. Deleted chromosome 5 was unstable and often involved in different types of cryptic unbalanced rearrangements. No true monosomy 5 was observed. Patients with CCA involving deleted chromosome 5 had an extremely poor prognosis (median overall survival, 2 months).
Institute of Hematology and Blood Transfusion Prague Czech Republic
Institute of Physiology 1st Faculty of Medicine Charles University Prague Czech Republic
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc14063686
- 003
- CZ-PrNML
- 005
- 20140709123958.0
- 007
- ta
- 008
- 140704s2014 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.leukres.2014.01.012 $2 doi
- 035 __
- $a (PubMed)24636338
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Zemanova, Zuzana $u Center of Oncocytogenetics, Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital and First Faculty of Medicine, Charles University in Prague, Czech Republic. Electronic address: zuze@vfn.cz.
- 245 10
- $a Involvement of deleted chromosome 5 in complex chromosomal aberrations in newly diagnosed myelodysplastic syndromes (MDS) is correlated with extremely adverse prognosis / $c Z. Zemanova, K. Michalova, H. Buryova, J. Brezinova, K. Kostylkova, D. Bystricka, M. Novakova, I. Sarova, S. Izakova, L. Lizcova, S. Ransdorfova, Z. Krejcik, MD. Merkerova, A. Dohnalova, M. Siskova, A. Jonasova, R. Neuwirtova, J. Cermak,
- 520 9_
- $a MDS with complex chromosomal aberrations (CCA) are characterized by short survival and a high rate of transformation to AML. A comprehensive genome-wide analysis of bone-marrow cells of 157 adults with newly diagnosed MDS and CCA revealed a large spectrum of nonrandom genomic changes related to the advanced stages of MDS. Chromosome shattering, probably resulting from chromothripsis, was found in 47% of patients. Deleted chromosome 5 was unstable and often involved in different types of cryptic unbalanced rearrangements. No true monosomy 5 was observed. Patients with CCA involving deleted chromosome 5 had an extremely poor prognosis (median overall survival, 2 months).
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 12
- $a chromozomální delece $7 D002872
- 650 12
- $a lidské chromozomy, pár 5 $7 D002895
- 650 _2
- $a srovnávací genomová hybridizace $7 D055028
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a karyotyp $7 D059785
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a myelodysplastické syndromy $x genetika $x mortalita $7 D009190
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a retrospektivní studie $7 D012189
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Michalova, Kyra $u Center of Oncocytogenetics, Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital and First Faculty of Medicine, Charles University in Prague, Czech Republic; Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
- 700 1_
- $a Buryova, Halka $u Center of Oncocytogenetics, Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital and First Faculty of Medicine, Charles University in Prague, Czech Republic.
- 700 1_
- $a Brezinova, Jana $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
- 700 1_
- $a Kostylkova, Karla $u Center of Oncocytogenetics, Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital and First Faculty of Medicine, Charles University in Prague, Czech Republic.
- 700 1_
- $a Bystricka, Dagmar $u Center of Oncocytogenetics, Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital and First Faculty of Medicine, Charles University in Prague, Czech Republic.
- 700 1_
- $a Novakova, Milena $u Center of Oncocytogenetics, Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital and First Faculty of Medicine, Charles University in Prague, Czech Republic.
- 700 1_
- $a Sarova, Iveta $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
- 700 1_
- $a Izakova, Silvia $u Center of Oncocytogenetics, Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital and First Faculty of Medicine, Charles University in Prague, Czech Republic.
- 700 1_
- $a Lizcova, Libuse $u Center of Oncocytogenetics, Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital and First Faculty of Medicine, Charles University in Prague, Czech Republic.
- 700 1_
- $a Ransdorfova, Sarka $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
- 700 1_
- $a Krejcik, Zdenek $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
- 700 1_
- $a Merkerova, Michaela Dostalova $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
- 700 1_
- $a Dohnalova, Alena $u Institute of Physiology, First Faculty of Medicine, Charles University in Prague, Czech Republic.
- 700 1_
- $a Siskova, Magda $u First Medical Department, General University Hospital and First Faculty of Medicine, Charles University in Prague, Czech Republic.
- 700 1_
- $a Jonasova, Anna $u First Medical Department, General University Hospital and First Faculty of Medicine, Charles University in Prague, Czech Republic.
- 700 1_
- $a Neuwirtova, Radana $u First Medical Department, General University Hospital and First Faculty of Medicine, Charles University in Prague, Czech Republic.
- 700 1_
- $a Cermak, Jaroslav $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
- 773 0_
- $w MED00003141 $t Leukemia research $x 1873-5835 $g Roč. 38, č. 5 (2014), s. 537-44
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/24636338 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20140704 $b ABA008
- 991 __
- $a 20140709124250 $b ABA008
- 999 __
- $a ok $b bmc $g 1031170 $s 862418
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2014 $b 38 $c 5 $d 537-44 $i 1873-5835 $m Leukemia research $n Leuk Res $x MED00003141
- LZP __
- $a Pubmed-20140704
